Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2022 | Story Leonie Bolleurs | Photo Stephen Collett
Prof Ted Kroon
Prof Ted Kroon from the Department of Physics recently delivered his inaugural lecture on the topic What’s the use of a rainbow on the UFS Bloemfontein Campus.

“A rainbow is a natural phenomenon, the result of the refraction and reflection of the sun’s rays in drops of rain. As far as mankind is concerned, it’s a perfectly useless object and won’t make anyone money. Yet the poet who said, My heart leaps up when I behold a rainbow in the sky, only put into word the feeling of wonder and excitement we all have when we see a rainbow.”

“Every day I see a rainbow in my work; I do not need to wait to see one in the sky,” says Prof Ted Kroon, Professor in the Department of Physics at the University of the Free State (UFS), who used this phenomenon to introduce the topic of his inaugural lecture: What’s the use of a rainbow. 

“Far from being only a colourful spectacle with no practical value, rainbows are useful – and lead to useful things,” he believes. 

According to Prof Kroon, one can find examples of real rainbows and rainbow analogies used not only in everyday life, but also in physics. “Besides it being familiar devices in literature, culture, and even marketing, studies of rainbows can yield practical engineering information and may even help us to find new habitable planets,” he says.

Inspired by the many uses of a rainbow

In his lecture, he discussed the basic features of natural rainbows and how they come about. He also explored how the rainbow gives meaning to colour, and how this relates to the temperature of objects. He looked at an array of instances where the rainbow is used; from depicting the life of a star to indicating that we are sick (a thermometer) or when we need to refill a gas cylinder.
Moreover, Prof Kroon pointed out that rainbows are used in computer chips, stress identification, and to transmit internet data through underwater cables of glass fibre. He also referred to how the rainbow was harnessed as an engineering tool to measure refractive index and characterise fine droplet sprays used in industry. 

He continues, “Remarkably, the science developed to understand the natural rainbow can be redirected and applied to the optical properties of metallic nanoparticles, allowing the development of nanotechnology. Knowing how the natural rainbow works and its limitations, better systems have been developed to produce rainbows. Such rainbows have been used to discover new elements and to determine the age of the universe.”

As a member of an international community of phosphor researchers who are privileged to work with rainbows every day, he has used them to study the light-emitting properties of materials doped with bismuth. With this project – an initiative with the African Laser Centre taking place between 2016 and 2021 – he collaborated with the University of Khartoum in Sudan and trained a number of its postgraduate students. “My role included the guidance of students and the measurement and interpretation of the light-emitting properties of the materials. Our research during this time, considering more than a dozen materials, was summarised in 34 scientific publications that contributed to a greater understanding of bismuth ions as light-emitting materials,” he explains. 

Developing new materials, efficient in emitting blue light

He has been developing luminescent materials since 2006, primarily for general lighting (fluorescent tubes and LEDs) and displays (television, computer, and cellphone screens), as well as niche applications in medical and forensic science. 

As part of his current research, he is examining the effect of plasmonic metal nanoparticles on phosphor light emission. He is also exploring materials that absorb infrared light but emit visible light. “For this, I would like to consider the long-term stability of such materials and develop new materials that are more efficient in emitting particularly blue light,” he says. 

Prof Kroon holds a C2 rating from the National Research Foundation and has published more than 150 articles and book chapters, obtaining a Scopus h-index of 26.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept